| Autor: |
Thieblemont, C., Fox, C. P., Wang, A., Sail, K., Alshreef, A., Moran, M., Mutebi, A., Blaedel, J., Chirikov, V., Salles, G. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p453-454, 2p |
| Abstrakt: |
Patients in EPCORE NHL-1 with prior CAR T therapy were excluded as ZUMA-1 included only patients without prior CAR T therapy. Efficacy of Subcutaneous Epcoritamab versus Axi-cel in R/R DLBCL CAR T-Naive and CAR T-eligible patients: An Indirect Comparison B Introduction: b Epcoritamab, an off-the-shelf, subcutaneous CD3xCD20 T-cell-engaging bispecific antibody that redirects T cells to eliminate malignant CD20+ B cells, showed single-agent efficacy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) with a manageable safety profile. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text